Results 311 to 320 of about 355,945 (323)
Some of the next articles are maybe not open access.
Anti‐20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28
Arthritis & Rheumatism, 2006AbstractObjectiveThe ubiquitin‐proteasome system plays a central role in cellular homeostasis as well as in regulation of the inflammatory and stress responses. However, the occurrence of autoantibodies against 20S proteasome has, to date, been considered to be a nonspecific epiphenomenon in patients with autoimmune disorders. This study was undertaken
Michael, Brychcy +6 more
openaire +2 more sources
2012
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as ...
openaire +2 more sources
2005
The proteasome is a highly complex, ATP-dependent protease, consisting of over 30 subunits, and dedicated mainly to the degradation of ubiquitin-protein conjugates. Proteasomes are evolutionarily conserved in the eukaryotic kingdom, and those of yeast are well suited to serve as a general model.
David S, Leggett +2 more
openaire +2 more sources
The proteasome is a highly complex, ATP-dependent protease, consisting of over 30 subunits, and dedicated mainly to the degradation of ubiquitin-protein conjugates. Proteasomes are evolutionarily conserved in the eukaryotic kingdom, and those of yeast are well suited to serve as a general model.
David S, Leggett +2 more
openaire +2 more sources
2002
In contrast to our detailed knowledge of prokaryotic proteasomes, we have only a limited understanding of the prokaryotic regulators and their functional interaction with the proteasome. Most probably, we will soon learn more about the molecular structure and the mechanism of action of the prokaryotic regulators.
openaire +3 more sources
In contrast to our detailed knowledge of prokaryotic proteasomes, we have only a limited understanding of the prokaryotic regulators and their functional interaction with the proteasome. Most probably, we will soon learn more about the molecular structure and the mechanism of action of the prokaryotic regulators.
openaire +3 more sources
[Proteasome and proteasome inhibitors].
Annales de dermatologie et de venereologie, 2006L, Meunier +5 more
openaire +1 more source